A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity of ASN-3186 in Patients with Advanced Solid Tumors.
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs AT 012 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Yahong Pharmaceutical Technology
- 29 Jan 2025 New trial record